About CureVac
CureVac is a publicly listed company based in Tubingen (Germany) founded in 2000 by Florian Von Der Mulbe, and was acquired by BioNTech in June 2025. MRNA-based therapeutics against cancer and infectious diseases are developed. CureVac has raised $975.35 million across 15 funding rounds from investors including BioNTech, Gates and Gates Foundation. The company has 660 employees. CureVac has completed 1 acquisition, including Frame Therapeutics. CureVac was last valued at $1.25 billion in June 2025. Its website curevac.com draws about 21 thousand monthly visits. CureVac offers products and services including mRNA Technology Platform and mRNA COVID-19 Vaccine. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is CureVac AG.
Company details
CureVac was established in 2000 in Tubingen, Germany, within the biotechnology sector. mRNA technologies are employed to create therapeutics targeting cancer and infectious diseases. RNAntibody platforms are used to produce functional antibodies and proteins from mRNA. Key investigational assets include CV9104, a vaccine for prostate cancer that activates immune responses, CV8102 for cutaneous melanoma, and CV9202 for non-small cell lung cancer. Focus remains on immunotherapy advancements across Europe.
- Headquarters Tubingen, Germany
- Employees 660
- Founders Florian Von Der Mulbe
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website curevac.com
- Social LinkedIn X Facebook YouTube
- Acquired by BioNTech (Jun 2025)
- Legal Name Curevac N.V.
- Annual Revenue$578.9 M (USD)896.07as on Dec 31, 2024
- Net Profit$175.44 M (USD)162.37as on Dec 31, 2024
- EBITDA$243.15 M (USD)188.28as on Dec 31, 2024
- Total Equity Funding$975.35M (USD)
in 15 rounds
- Latest Funding Round$299M (USD), Grant
Sep 2020
- InvestorsBioNTech
& 16 more
- Employee Count660
- Investments & Acquisitions
- Acquired byBioNTech
(Jun 2025)
Products & Services of CureVac
CureVac offers a comprehensive portfolio of products and services, including mRNA Technology Platform and mRNA COVID-19 Vaccine.
Platform for developing mRNA-based medicines and vaccines.
Program focused on mRNA vaccines for COVID-19 prevention.
Apps and channels of CureVac
its YouTube channel CureVac has 618 subscribers and 7 videos.
Videos from CureVac
The most watched videos on CureVac's YouTube channel, CureVac (618 subscribers). Click a video to play it here.
More on CureVac.
Funding Insights of CureVac
CureVac has successfully raised a total of $975.35M across 15 strategic funding rounds. The most recent funding activity was a Grant round of $299 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $975.35M
- Total Rounds 15
- Last Round Grant β $299M
- First Round $3.41M
(Jun 2003)
- Investors Count 17
Latest 10 of 15 funding rounds of CureVac with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $299M | Grant | β | β | β |
| Jul 2020 | $126M | Series F | β | Qatar Investment Authority | β |
| Jul 2020 | $171M | Series F | β | GSK | β |
| Jul 2020 | $84.33M | Debt – Conventional | β | β | |
| Jun 2020 | $343M | Series F | β | Bundesregierung | β |
| Jun 2019 | $10.29M | Grant | β | β | |
| Feb 2019 | $34.1M | Grant | β | β | |
| Feb 2018 | Series E | β | Gates Foundation | β | |
| Nov 2016 | $29.5M | Series E | β | Baden-Wurttemberg Medical Care Agency, L-Bank | β |
| Nov 2015 | $110.25M | Series E | β | Baillie Gifford |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of CureVac
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $1.25B (Jun 2025). 17 investors in total: 17 institutional.
Investors in CureVac
CureVac has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include BioNTech, Gates and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are targeted by this private equity firm. | 2017 | cepi.net | Oslo, Norway | |
Investments are made in life and health sciences companies. | dievini.de | Germany | ||
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
| hyfinityfund.com | ||||
A sovereign wealth fund backed by Qatar, managing investments and funds. | 2005 | qia.qa | Doha, Qatar | |
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom | |
Official information and updates are provided by the German Federal Government. | bundesregierung.de | Berlin, Germany | ||
Administration of patents and trademarks in the United States. | uspto.gov | |||
Legal services on patents and innovation are provided across Europe. | 1998 | epo.org | Munich, Germany | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for CureVac
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CureVac
113 people are tracked at CureVac (47 in leadership, 4 in board & advisors, 62 in team); the tracked headcount is 660.
| Name | Role | Group |
|---|---|---|
Florian Von Der Mulbe | Co-Founder & CPO | Leadership |
Alexander Zehnder | CEO | Leadership |
Malte Greune | Chief Operating Officer | Leadership |
Axel Sven Malkomes | CFO | Leadership |
Mark Caroli | Vice President Supply Chain Management | Leadership |
Felipe Pereira | Global Director Supply Chain Planning | Leadership |
Nicole Luft | Director Direct Procurement | Leadership |
Thaminda Ramanayake | Chief Business & Strategy Officer | Leadership |
Dr. Marco Rau | General Counsel - Executive Vice President Legal & Compliance | Leadership |
Giulia Povellato | Vice President, Global Programme Head - Urinary Tract Infections | Leadership |
Miriam Schmid | Senior Director Strategic Portfolio Management | Leadership |
Inma Muniz | Project Director Digital And Data | Leadership |
Ulrike Gnad-Vogt | Interim Chief Development Officer | Leadership |
Myriam Mendila | Chief Scientific Officer & Head, R&D | Leadership |
Tobias Seibel | Associate Director Translational And Clinical Science | Leadership |
Arlène Derbaix | VP Product Development Operations, Program And Portfolio Management | Leadership |
Nils Hamann | Senior Director Quality Manufacturing & QP | Leadership |
Dr. Dominik Esslinger | Senior Director Digital & Data Services For Operations | Leadership |
Christian Ellinger | Director Business Development & Licensing | Leadership |
Dr. Yvonne Gebhardt | VP Manufacturing | Leadership |
93 more people are available in the full profile.
Complete people profiles for CureVac
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CureVac
CureVac is a publicly listed company on the NASDAQ with ticker symbol CVAC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 May 2021
- Listed onLSE: 0A9E
- Listed entityCureVac N.V.
- Exchange sectorHealth technology
- ISINNL0015436031
- Share price$4.66 (-0.21% on the day) · 2026-01-07
- Market capitalisation$1.05B
- Price to earnings6.5
- EPS (diluted, trailing year)$0.71
- Volume (last session)1,149,400
- Analyst consensusNeutral
Financials of CureVac
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $578.9M | $175.4M | $243.2M |
| 2023 | $58.1M | -$281.3M | -$275.4M |
| 2022 | $70.9M | -$261.7M | -$272.7M |
| 2021 | $121.7M | -$486.6M | -$1.20B |
| 2020 | $55.7M | -$147.2M | -$136.1M |
Detailed financial statements for CureVac
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CureVac
CureVac has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Frame Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Immunotherapies and personalized vaccines for cancer are developed. | frametherapeutics.com | Amsterdam, Netherlands | 2018 | Jun 2022 | $34.2M |
Complete acquisition details for CureVac
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of CureVac
7 dated milestones of CureVac across 25 years, from founding to its latest funding, stage changes and deals.
- Founded CureVac is founded.
- Funding First funding round of $3.4M.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Grant, of $299.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Frame Therapeutics.
- Exit Acquired by BioNTech.
Web traffic of CureVac
The website of CureVac (curevac.com) receives about 21.2K visits a month and ranks #1,260,361 among all websites worldwide, #1,597 in Biotechnology and Pharmaceuticals.
- Monthly visits21.2K
▲ 9.4% vs previous month
- Unique visitors8.5K
per month
- Global rank#1,260,361
among all websites
- Category rank#1,597
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.5
- Average visit1 min 31 sec
- DevicesDesktop 26% Β· Mobile 74%
Websites whose visitors overlap most with CureVac. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| immatics.com | 100% | 17.1K | #1,492,078 | View details | |
| immunocore.com | 92% | 11.9K | #2,192,904 | View details | |
biontech.de | biontech.de | 87% | #522,738 | β | |
cpmda.org.tw | cpmda.org.tw | 85% | #1,393,044 | β | |
news.gbimonthly.com | news.gbimonthly.com | 51% | #720,971 | β |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Curevac
Complete news archive for CureVac
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CureVac
CureVac was founded in 2000 and raised its 1st funding round 3 years after it was founded.
CureVac is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.
CureVac is a funded company, having raised a total of $975.35M across 15 funding rounds to date. The company's 1st funding round was a Series E of $110.25M, raised on Jun 2003.
CureVac has 660 employees.
Annual revenue of CureVac is $578.9M as on Dec 31, 2024.
CureVac was established in 2000 in Tubingen, Germany, within the biotechnology sector. mRNA technologies are employed to create therapeutics targeting cancer and infectious diseases. RNAntibody platforms are used to produce functional antibodies and proteins from mRNA. Key investigational assets include CV9104, a vaccine for prostate cancer that activates immune responses, CV8102 for cutaneous melanoma, and CV9202 for non-small cell lung cancer. Focus remains on immunotherapy advancements across Europe.
CureVac offers mRNA Technology Platform and mRNA COVID-19 Vaccine.
Yes, CureVac is publicly traded on NASDAQ under the ticker symbol CVAC.
CureVac has made 1 acquisition, including Frame Therapeutics.
CureVac has 17 investors. Key investors include BioNTech, Gates, Gates Foundation, Baillie Gifford, and European Investment Bank.
The valuation of CureVac is $1.25B as of Jun 2025.
CureVac operates through Curevac Ag.

